2015 Breast Cancer CollectionBreast Cancer Ribbon

We invite you to explore The Oncologist's multidisciplinary collection of original research and reviews on advances in in the diagnosis, pathology, and treatment of breast cancer. This collection covers diverse topics of interest to clinicians, including advances in genomic testing, biomarker analyses, and molecular classification, as well as treatment-related side effects, outcome disparities, and a short series on breast cancer in men.

Subscribe to our RSS feed to ensure you receive the latest in breast cancer research from The Oncologist.

The Role of CDK4/6 Inhibition in Breast Cancer

Irit Ben-Aharon, Tal Granot, Israel Meizner, Noa Hasky, Ana Tobar, Shulamith Rizel, Rinat Yerushalmi, Avi Ben-Haroush, Benjamin Fisch, and Salomon M. Stemmer

The Oncologist 2015; 20:483-490; first published on April 15, 2015; doi:10.1634/theoncologist.2014-0443

Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer

Olivier Humbert, Alexandre Cochet, Bruno Coudert, Alina Berriolo-Riedinger, Salim Kanoun, François Brunotte, Pierre Fumolea

The Oncologist 2015; 20:94-104; first published on January 5, 2015; doi:10.1634/theoncologist.2014-0342

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

Maggie C.U. Cheang, Miguel Martin, Torsten O. Nielsen, Aleix Prat, David Voduc, Alvaro Rodriguez-Lescure, Amparo Ruiz, Stephen Chia, Lois Shepherd, Manuel Ruiz-Borrego, Lourdes Calvo, Emilio Alba, Eva Carrasco, Rosalia Caballero, Dongsheng Tu, Kathleen I. Pritchard, Mark N. Levine, Vivien H. Bramwell, Joel Parker, Philip S. Bernard, Matthew J. Ellis, Charles M. Perou, Angelo Di Leo, Lisa A. Carey

The Oncologist 2015; 20:474-482; first published on April 23, 2015; doi:10.1634/theoncologist.2014-0372

Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials

Mellissa Hicks, Erin R. Macrae, Mahmoud Abdel-Rasoul, Rachel Layman, Susan Friedman, Jenny Querry, Maryam Lustberg, Bhuvaneswari Ramaswamy, Ewa Mrozek, Charles Shapiro, Robert Wesolowski

The Oncologist 2015; 20:337-343; first published on March 2, 2015; doi:10.1634/theoncologist.2014-0334

Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer

Shoshana M. Rosenberg, Annette L. Stanton, Keith J. Petrie, Ann H. Partridge

The Oncologist 2015; 20:598-604; first published on May 1, 2015; doi:10.1634/theoncologist.2015-0007

Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis

Qi Shen, Aysegul A. Sahin, Kenneth R. Hess, Dima Suki, Kenneth D. Aldape, Raymond Sawaya, Nuhad K. Ibrahim

The Oncologist 2015; 20:466-473; first published on March 23, 2015; doi:10.1634/theoncologist.2014-0107

Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity

Irit Ben-Aharon, Tal Granot, Israel Meizner, Noa Hasky, Ana Tobar, Shulamith Rizel, Rinat Yerushalmi, Avi Ben-Haroush, Benjamin Fisch, Salomon M. Stemmer

The Oncologist 2015; 20:985-991; first published on June 22, 2015; doi:10.1634/theoncologist.2015-0044

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing

Zahi I. Mitri, Michelle Jackson, Carolyn Garby, Juhee Song, Sharon H. Giordano, Gabriel N. Hortobágyi, Claire N. Singletary, S. Shahrukh Hashmi, Banu K. Arun, and Jennifer K. Litton

The Oncologist 2015; 20:593-597; first published on May 6, 2015; doi:10.1634/theoncologist.2014-0425

Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series

Giovanna Masci, Michele Caruso, Francesco Caruso, Piermario Salvini, Carlo Carnaghi, Laura Giordano, Vittoria Miserocchi, Agnese Losurdo, Monica Zuradelli, Rosalba Torrisi, Luca Di Tommaso, Corrado Tinterri, Alberto Testori, Carlos A. Garcia-Etienne, Wolfgang Gatzemeier, Armando Santoro

The Oncologist 2015; 20:586-592; first published on May 6, 2015; doi:10.1634/theoncologist.2014-0243

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, Antonino Maiorana, Guido Ficarra, Stefania Bettelli, Enrico Tagliafico, Silvio Bicciato, Daniele Giulio Generali, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Antonino Musolino, Catherine Ellis, Rocco Crescenzo, PierFranco Conte

The Oncologist 2015; 20:1001-1010; first published on August 5, 2015; doi:10.1634/theoncologist.2015-0138

Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab

Lu Cao, Gang Cai, Cai Chang, Ai-Yu Miao, Xiao-Li Yu, Zhao-Zhi Yang, Jin-Li Ma, Qian Zhang, Jiong Wu, Xiao-Mao Guo, Jia-Yi Chen

The Oncologist 2015; 20:605-614; first published on May 1, 2015; doi:10.1634/theoncologist.2014-0299

BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer

Nagi S. El Saghir, Nathalie K. Zgheib, Hussein A. Assi, Katia E. Khoury, Yannick Bidet, Sara M. Jaber, Raghid N. Charara, Rania A. Farhat, Firas Y. Kreidieh, Stephanie Decousus, Pierre Romero, Georges M. Nemer, Ziad Salem, Ali Shamseddine, Arafat Tfayli, Jaber Abbas, Faek Jamali, Muhieddine Seoud, Deborah K. Armstrong, Yves-Jean Bignon, Nancy Uhrhammer

The Oncologist 2015; 20:357-364; first published on March 16, 2015; doi:10.1634/theoncologist.2014-0364

Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women

Laura C. Collins, Shari Gelber, Jonathan D. Marotti, Sarah White, Kathryn Ruddy, Elena F. Brachtel, Lidia Schapira, Steven E. Come, Virginia F. Borges, Pepper Schedin, Ellen Warner, Taylor Wensley, Rulla M. Tamimi, Eric P. Winer, Ann H. Partridge

The Oncologist 2015; 20:713-718; first published on May 29, 2015; doi:10.1634/theoncologist.2014-0412

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

Xavier Pivot, Laura Mansi, Loic Chaigneau, Philippe Montcuquet, Antoine Thiery-Vuillemin, Fernando Bazan, Erion Dobi, Jean L. Sautiere, Frederic Rigenbach, Marie P. Algros, Steve Butler, Farid Jamshidian, Phillip Febbo, Christer Svedman, Sophie Paget-Bailly, Franck Bonnetain, Christian Villanueva

The Oncologist 2015; 20:344-350; first published on March 20, 2015; doi:10.1634/theoncologist.2014-0198

Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

Marta Bonotto, Lorenzo Gerratana, Donatella Iacono, Alessandro Marco Minisini, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi

The Oncologist 2015; 20:719-724; first published on May 27, 2015; doi:10.1634/theoncologist.2015-0002

Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors

José M. Serrano, Iria González, Silvia Del Castillo, Javier Muñiz, Luis J. Morales, Fernando Moreno, Rosa Jiménez, Carmen Cristóbal, Catherine Graupner, Pedro Talavera, Alejandro Curcio, Paula Martínez, Juan A. Guerra, and Joaquín J. Alonso

The Oncologist 2015; 20:864-872; first published on July 16, 2015; doi:10.1634/theoncologist.2014-0500

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study

Joseph Gligorov, Xavier B. Pivot, William Jacot, Hervé L. Naman, Dominique Spaeth, Jean-Louis Misset, Rémy Largillier, Jean-Loup Sautiere, Anne de Roquancourt, Christophe Pomel, Philippe Rouanet, Roman Rouzier, Frederique M. Penault-Llorca, and for The Francilian Breast Intergroup

The Oncologist 2015; 20:873-879; first published on June 25, 2015; doi:10.1634/theoncologist.2014-0467

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

Matteo Lambertini, Arlindo R. Ferreira, Francesca Poggio, Fabio Puglisi, Antonio Bernardo, Filippo Montemurro, Elena Poletto, Emma Pozzi, Valentina Rossi, Emanuela Risi, Antonella Lai, Elisa Zanardi, Valentina Sini, Serena Ziliani, Gabriele Minuti, Silvia Mura, Donatella Grasso, Andrea Fontana, Lucia Del Mastro

The Oncologist 2015; 20:880-889; first published on June 22, 2015; doi:10.1634/theoncologist.2015-0020

Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction

Anthony F. Yu, Nandini U. Yadav, Anne A. Eaton, Betty Y. Lung, Howard T. Thaler, Jennifer E. Liu, Clifford A. Hudis, Chau T. Dang, Richard M. Steingart

The Oncologist 2015; 20:1105-1110; first published on August 3, 2015; doi:10.1634/theoncologist.2015-0125

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram

Agnese Barnabei, Lidia Strigari, Paolo Marchetti, Valentina Sini, Liana De Vecchis, Salvatore Maria Corsello, Francesco Torino

The Oncologist 2015; 20:1111-1118; first published on September 4, 2015; doi:10.1634/theoncologist.2015-0183



Monitoring Cancer Through Circulating Tumor CellsDaniel A. Haber, MD, PhDChabner Colloquium 2015
Genomic Characterization of CNS Metastases: Implications for Precision MedicinePriscilla K. Brastianos, MDChabner Colloquium 2015
The "BRCA-Like" Phenotype in CancerLeif W. Ellisen, MD, PhDChabner Colloquium 2015